U.S. President Donald Trump participates in a bilateral meeting with Finnish President Alexander Stubb (not pictured) in the Oval Office of the White House on October 9, 2025 in Washington, DC, USA.
Nathan Howard | Reuters
Trump administration and AstraZeneca On Friday, the British-based pharmaceutical giant announced it had reached an agreement to lower drug prices in the United States.
The deal with AstraZeneca builds on a similar agreement with the U.S. drugmaker. pfizerIt was announced late last month.
AstraZeneca has agreed to sell the drug directly to Medicaid patients on an upcoming government website, TrumpRx.gov, at the lowest price offered in other developed countries, or what President Trump calls “most-favoured-nation” pricing. AstraZeneca’s primary care drugs will be available on the site starting early next year, and the company plans to offer the new prescription drugs at most-favoured-nation prices, said Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services.
AstraZeneca CEO Pascal Soriot also said that as part of the deal, the company would be exempt from tariffs on medicines. Pfizer also agreed to similar terms with the Trump administration, receiving a three-year carve-out from drug tariffs in exchange for continued investment in U.S. manufacturing.
AstraZeneca announced in July that it would invest $50 billion in the U.S. by 2030. The company announced details of these plans on Friday, ahead of the reported price agreement announcement.
President Donald Trump, administration officials and Mr. Soriot announced the agreement at a White House event on Friday.
MSNBC earlier reported on the deal.
President Trump is pushing drug companies to lower prices and ramp up manufacturing in the U.S., as drug prices soaring compared to other developed countries trouble voters across political lines. Many drug companies have announced major investments in the U.S. in recent months, as the administration has threatened to impose tariffs as high as 250% on pharmaceutical companies.
President Trump has said he aims to reach price agreements with other big drug companies in the coming weeks. President Trump suggested that pharmaceutical companies and other companies are making similar investments due to the threat of higher tariff costs.
“Most of them are here because of the tariffs,” he says.
